Skip to content

24 Hours Moisturization Potential of Varenya Multiple Skin Care Products

A Clinical Study to evaluate the 24 Hours Moisturization Potential of Varenya Multiple Skin Care Products - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102259
Enrollment
32
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Multiple skin care products: Route of administration: Topical, Frequency: 2-3gm cream or 1 drop oil over one hand, Duration: 24 hours Control Intervention1: Not Applicable

Sponsors

Varenya Elixir Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female 18 to 45 2) Subjects willing to give written informed consent. 3) Volunteers with Normal skin 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last years, or any other confounding skin condition. 3. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 4. Have participated in any interventional clinical trial in the previous 90 days. 5. Have a known sensitivity to any of the constituents of the test product 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids

Design outcomes

Primary

MeasureTime frame
Change in hydration Change in TEWL Timepoint: T0 Min, T30 Min, T2 HR, T8 HR, T24 HR

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026